Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000
(Thomson Reuters ONE) -
Novartis International AG /
Novartis confirms growing Gilenya® clinical and real-world experience as number
of patients treated increases to over 63,000
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Growing global evidence base reinforces consistent and sustained efficacy of
first once-daily oral multiple sclerosis treatment
* Up to seven years of clinical trial experience (Phase II and III) and over
two years of real-world use
* Gilenya is the only approved MS treatment shown to consistently decrease
brain volume loss across studies with a significant effect seen as early as
six months
* Low rate of brain volume loss with Gilenya sustained for up to four years in
Phase III studies and for up to seven years in patients after completing a
Phase II study
Basel, March 26, 2013 - Latest global patient-use data show that Gilenya(®)
(fingolimod) has been used to treat more than 63,000 patients in clinical trials
and the post-marketing setting[1].
"As the first once-daily oral MS therapy, we are pleased Gilenya has played such
an important role in addressing unmet medical need in the MS community in the
two years following initial approvals," said David Epstein, Head of the
Pharmaceuticals Division of Novartis Pharma AG. "Our growing experience
reinforces Gilenya's high efficacy and very good tolerability profile and
Novartis remains committed to ensuring eligible patients have access to
Gilenya."
Gilenya is the only approved treatment shown to consistently decrease brain
volume loss[2],[3]. Brain volume loss is the best magnetic resonance imaging
(MRI) correlate of long-term disability. New data presented at the recent 65th
Annual Meeting American Academy of Neurology (AAN), showed that Gilenya reduced
the rate of brain volume loss by about one-third compared to interferon beta-1a
IM or placebo in studies with over 3,600 patients with relapsing MS.[4] Patients
from a Phase II study who remained on treatment for up to seven years
experienced consistently low rates of brain volume loss[5].
Data has also shown significant efficacy with Gilenya in reducing relapses and
slowing of six-month disability progression sustained at four years[6]. Nearly
half of Gilenya patients were disease-free after one year of treatment[7],[8]
and in the pivotal FREEDOMS study, eight out of ten patients on the approved
dose remained on treatment at two years[2].
In clinical trials Gilenya exhibited a well-characterized safety profile and
very good tolerability profile[2],[3].
Gilenya was approved based on the largest phase III clinical trial program in MS
at the time of submission, which included a head-to-head study versus Avonex®
(interferon beta-1a IM), a commonly prescribed treatment. Gilenya is now
approved in 70 countries, and there is approximately 73,000 patient years of
exposure[1].
Up to 2.5 million people worldwide are affected with MS[9], a neurodegenerative
condition that often begins in early adulthood[10]. Around 70% of newly
diagnosed patients with MS are in the prime of their lives - between 20 and 40
years of age - so most people are employed at the time of diagnosis. This can
have a significant impact on careers, quality of life and families[11],[12].
About Gilenya
Gilenya is the first oral therapy approved to treat relapsing forms of MS and
the first in a new class of compounds called sphingosine 1-phosphate receptor
(S1PR) modulators. Gilenya is thought to act on inflammatory processes
implicated in the MS disease process[13],[14].
Gilenya has demonstrated superior efficacy compared to Avonex® (interferon beta-
1a IM), a commonly prescribed treatment, showing a 52% relative reduction in
annualized relapse rate (primary endpoint) at one year in a pivotal head-to-head
trial in patients with relapsing-remitting multiple sclerosis[3]. In a post hoc
sub-group analysis, Gilenya showed a 61% relative reduction in annualized
relapse rate compared to interferon-beta-1a IM at one year in subgroups of
patients with highly active relapsing-remitting MS not responding to interferon
treatment[15].
In clinical trials Gilenya exhibited a well-characterized safety profile and
very good tolerability profile[2],[3]. The most common side effects were
headache, liver enzyme elevations, influenza, diarrhea, back pain, and cough.
Other Gilenya-related side effects included transient, generally asymptomatic,
heart rate reduction and atrioventricular block upon treatment initiation, mild
blood pressure increase, macular edema, and mild bronchoconstriction[2],[3]. The
rates of infections overall, including serious infections, were comparable among
treatment groups, although a slight increase in lower respiratory tract
infections (primarily bronchitis) was seen in patients treated with Gilenya. The
number of malignancies reported across the clinical trial program was small,
with comparable rates between the Gilenya and control groups[2],[3].
Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "committed," or similar expressions, or by express or
implied discussions regarding potential new indications or labeling for Gilenya
or regarding potential future revenues from Gilenya. You should not place undue
reliance on these statements. Such forward-looking statements reflect the
current views of management regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results
with Gilenya to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that Gilenya will be submitted or approved for any additional indications or
labeling in any market, or at any particular time. Nor can there be any
guarantee that Gilenya will achieve any particular levels of revenue in the
future. In particular, management's expectations regarding Gilenya could be
affected by, among other things, unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general, including potential competition from
additional newly-approved oral multiple sclerosis treatments; unexpected
regulatory actions or delays or government regulation generally; government,
industry and general public pricing pressures; unexpected manufacturing issues;
the company's ability to obtain or maintain patent or other proprietary
intellectual property protection; the impact that the foregoing factors could
have on the values attributed to the Novartis Group's assets and liabilities as
recorded in the Group's consolidated balance sheet, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those anticipated, believed, estimated or expected.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 128,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References:
[1] Data on file. Novartis Pharma AG.
[2] Kappos L. et al; for FREEDOMS Study Group. A placebo-controlled trial of
oral fingolimod in relapsing multiple sclerosis. N Engl J Med.
2010;362(5):387-401.
[3] Cohen JA, Barkhof F, Comi G, et al; for TRANSFORMS Study Group. Oral
fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl
J Med. 2010;362(5):402-415
[4] Cohen J. et al. Fingolimod-effect on brain atrophy and clinical/MRI
correlations in Three Phase 3 studies - TRANSFORMS, FREEDOMS and FREEDOMS II.
Abstract Presented at AAN, San Diego, March 2013.
[5] Chin PS, Calabresi PA, Zhang Y, von Rosenstiel P, Kappos L. Early effect of
fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis.
Poster presented at: 28th Congress of the European Committee for Treatment and
Research in Multiple Sclerosis; October 10-13, 2012: Lyon, France. Abstract P459
[6] Kappos L. et al. Phase 3 FREEDOMS study extension: fingolimod (FTY720)
efficacy in patients with relapsing-remitting multiple sclerosis receiving
continuous or placebo-fingolimod switched therapy for up to 4 years. Poster
presented at: 28th Congress of the European Committee for Treatment and Research
in Multiple Sclerosis; October 10-13, 2012: Lyon, France. Poster P979.
[7] Khatri B. et al. Fingolimod treatment increases the proportion of patients
who are free from disease activity in multiple sclerosis compared to interferon
beta-1a: results from a phase 3 activecontrolled study (TRANSFORMS). Abstract
presented at: 64th AAN Annual Meeting; April 21-28, 2012; New Orleans, LA.
Abstract PD5:006.
[8] Khatri B. et al. Fingolimod treatment increases the proportion of patients
who are free from disease activity in multiple sclerosis compared to interferon
beta-1a: results from a phase 3 active-controlled study (TRANSFORMS). Poster
presented at: 64th AAN Annual Meeting; April 21-28, 2012; New Orleans, LA.
Poster PD5:006.
[9] Multiple Sclerosis International Federation. Atlas of MS [online]. Available
at: www.atlasofms.org. Accessed January 2013.
[10] Declaration of the European Parliament of 13 September 2012 on tackling
multiple sclerosis in Europe
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-
2012-0357&format=XML&language=EN. Accessed January 2013.
[11] European Multiple Sclerosis Platform, MS fact sheet 2011 http://www.ms-in-
europe.org/multiple-sclerosis/index.php?kategorie=whatisms&cnr=6&anr=127.
Accessed January 2013.
[12] Multiple Sclerosis Factsheet http://www.emsp.org/ms-
need/content/factsheet.pdf Accessed January 2013.
[13] Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects
in the immune and the central nervous system. Br J Pharmacol
2009;158(5):1173-1182.
[14] Chun J, Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in
Multiple Sclerosis. Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101.
[15] Havrdová E. et al. Clinical outcomes in subgroups of patients with highly
action relapsing-remitting multiple sclerosis treated with Fingolimod (FTY720):
Results from the FREEDOMS and TRANSFORMS phase III studies. Poster presented at
ECTRIMS, Amsterdam, October 2011.
Avonex® is a registered trademark of Biogen Idec.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Katrina Lucking
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 1218 (direct)
+41 79 593 4202 (mobile) +41 79 171 8267 (mobile)
eric.althoff(at)novartis.com katrina.lucking(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1688111/553709.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1688111]
Unternehmensinformation / Kurzprofil:
Datum: 26.03.2013 - 07:16 Uhr
Sprache: Deutsch
News-ID 242912
Anzahl Zeichen: 15311
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 355 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
